Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
_↗ investors.absci.com
News Image

A new collaboration has been announced between Oracle Cloud Infrastructure (OCI), AMD, and Abscia clinical-stage biotech company that leverages generative AI to develop novel therapeutics. This partnership aims to accelerate Absci’s drug discovery processes. This partnership allows Absci to consolidate its infrastructure and speed up its biologic design cycles by leveraging OCI's AI infrastructure and AMD's advanced hardware.

The core of this collaboration is to utilize OCI as the technical foundation for developing AI models and scaling AI workflows, which has already enabled Absci to accelerate the development of its AI Drug Creation Platform. This includes handling large-scale molecular-dynamics (MD) simulations and comprehensive antibody design. To further enhance performance and scalability, Absci is partnering with AMD to integrate the next-generation Instinct™ MI355X GPUs into its platform.

According to Sean McClain, founder and CEO of Absci, the collaboration pairs their cutting-edge AI models with best-in-class infrastructure, which will accelerate their ability to bring novel therapeutics to patients and establish a technical foundation for future AI-powered drug discovery. Dan Spellman, vice president of AI and OCI at Oracle, noted that Absci's generative AI-driven drug discovery is an ideal use case for OCI, which provides predictable performance through a combination of bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage. These features provide the low-latency networking and throughput that Absci needs for large-scale model training and high-resolution molecular-dynamics simulations. Ram Peddibhotla, corporate vice president of Data Center GPU Cloud Business at AMD, expressed pride in supporting Absci’s mission. He stated that the combination of OCI with AMD EPYC CPUs, AMD Instinct GPUs, and the open ROCm software platform delivers the performance and scalability required to advance complex biologics design and support more efficient discovery workflows. Absci's Integrated Drug Creation™ platform uses a continuous feedback loop between advanced AI algorithms and wet lab validation to refine data and strengthen models, facilitating rapid innovation and enhancing the precision of its therapeutic designs.

Log In
Sign Up